ADENOCARCINOMA DENGAN MUTASI EGFR
Abstract
Abstrac. Lung cancer is one of the leading causes of death worldwide. Global Cancer Statistic shows the average age of lung cancer is 70 years. Based on the PIONEER study showed high EGFR (Epidermal Growth Factor receptor) mutations in lung adenocarcinoma. EGFR mutations are found more in females than males, more commonly found in nonsmokers, with racial asia. EGFR mutations occur in exons 18, 19, 20, 21. EGFR examination is recommended for lung cancer type adenocarcinoma and type of squamous cell carcinoma.
Keyword : Adenocarcinoma kanker paru, mutatasi EGFR
Abstrak. Kanker paru merupakan salah satu penyebab kematian utama di seluruh dunia. Global Cancer Statistic menunjukkan usia rata-rata kanker paru adalah 70 tahun. Berdasarkan studi PIONEER menunjukkan mutasi EGFR (Epidermal Growth Factor receptor) tinggi pada Adenocarcinoma paru. Mutasi EGFR ditemukan lebih banyak pada perempuan dibandingkan laki-laki, lebih sering ditemukan pada bukan perokok, dengan rasasia. Mutasi EGFR terjadi pada exon 18, 19,20,21.
Pemeriksaan EGFR di anjurkan untuk kanker paru jenis adenocarcinoma dan jenis squamous cell carcinoma.
Keyword : Lung Cancer, Adenocarcinoma, EGFR Mutation
Keywords
References
Referensi
William D travis, Brambilla, Allen P. Burke, Alexander Marx, Andrew G. Nicholson. WHO Classification of Tumours of the lung, Pleura, Thymus dan Heart. Lyon. 2015
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90
Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with Advanced Non-Small- Cell Lung Cancer of Adenocarcinoma histology (PIONEER). J ThoracOncol. 2014;9:154–62.
Crinò L, Weder W, van Meerbeeck J, Felip E; ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2010;21(Suppl 5):v103–v115.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011;12:735–742.
Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J ClinOncol2009;27:6251–6266.
Pedomannasionalpelayanankankerparu .kementriankesehatan . 2016
www.nccn.org accessed on sept 20st , 2017 NCCN Clinical Practice Guidelines in Oncology NSCLC 2017
Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 2012;11:2535–2540.
DOI: 10.24815/jks.v18i1.11216
Refbacks
- There are currently no refbacks.